期刊文献+

治疗复发性多发性硬化症新药——特立氟胺 被引量:3

下载PDF
导出
摘要 复发性多发性硬化症(RMS)是一种中枢神经系统的慢性炎性自身免疫性疾病,女性发病率至少是男性的两倍。患者往往会出现疲倦、视力衰退、行走不稳、身体麻木、眩晕甚至小便失禁等问题,严重影响日常生活。在发病15年后、患者多需要辅具等装置,30%需以轮椅代步[1]。磁共振如显示多发性脑白质缺损,则5年内患病率高达60%。此外,磁共振还可以反映多发性硬化症病情的严重性(脑白质内病灶的数量和大小与多发性硬化症状正相关),并能揭示亚临床隐匿性病灶(无临床症状的脱髓鞘病灶)[2]。对大多数患者来说,发病早期会有多次复发和缓解,
机构地区 开滦总医院
出处 《中国药师》 CAS 2013年第12期1928-1930,共3页 China Pharmacist
  • 相关文献

参考文献14

  • 1Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis[J]. Am J Manag Care, 2013, 19(2 Suppl):S15-20.
  • 2Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis:a meta-analysis of randomised trials[J]. Lancet Neurol, 2013,12(7):669-676.
  • 3Oh J, O'Connor PW. An update of teriflunomide for treatment of multiple sclerosis[J]. Ther Clin Risk Manag, 2013,9:177-190.
  • 4李琦,胡婷婷,徐薇.多发性硬化症与调节性T细胞[J].国际检验医学杂志,2010,31(4):362-363. 被引量:1
  • 5Oh S, Cudrici C, Ito T, et al. B-cells and humoral immunity in multiple sclerosis. Implications for therapy[J]. Immunol Res, 2008,40(3):224-234.
  • 6Zeyda M, Poglitsch M, Geyeregger R, et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide:involvement of impaired integrin activation and immunologic synapse formation[J]. Arthritis Rheum, 2005,52(9):2730-2739.
  • 7Hail N Jr, Chen P, Kepa JJ, et al. Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective teriflunomide-induced apoptosis in transformed versus normal human keratinocytes[J]. Apoptosis,17(3):258-268.
  • 8Claussen MC,Korn T. Immune mechanisms of new therapeutic strategies in MS:teriflunomide[J]. Clin Immunol,2012, 142(1):49-56.
  • 9Erra M, Moreno I, Sanahuja J, et al. Biaryl analogues of teriflunomide as potent DHODH inhibitors[J]. Bioorg Med Chem Lett,2011,21(24):7268-7272.
  • 10RxList.AUBAGIO[EB/OL].http://www.rxlist.com/aubagio-drug.htm, 2012-09-21/2013-02-21.

二级参考文献22

  • 1Hafler DA,Compston A,Sawcer S,et al.Novel risk alleles for multiple sclerosis indentified by a whole genome association study[J].N Engl J Med,2007,357:851-862.
  • 2Miller DH,Khan OA,Sheremata WA,et al.A controlled trial of natalizumab for relapsing multiple sclerosis[J].New Eng J Med,2003,348:15-23.
  • 3Lehnart S,Massillon L,Follett P,et al.Activation of innate immunity in the CNS triggers neurodegeneration through a tool-like receptor 4-dependent pathway[J].Proc Natl Acad Sci USA,2003,100(14):8514-8519.
  • 4Monje ML,Toda H,Palmer TD.Inflammatory blockade restores adult hippocampal neurogenesis[J].Science,2003,302(5651):1760-1765.
  • 5Mycko MP,Papoian R,Boschert U,et al.Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis[J].Clin Neurol Neurosurg,2004,106(3):223-229.
  • 6Ledeboer A,Brevé JJ,Poole S,et al.Interleukin-10,interleukin-4,and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells[J].Glia,2000,30(2):134-142.
  • 7Ayers MM,Hazelwood LJ,Catmull DV,et al.Early glial responses in murine models of multiple sclerosis[J].Neurochem Int,2004,45(23):409-419.
  • 8Trajkovic V,Vuckovic O,Stosic-Grujicic S,et al.Astrocyte-induced regulatory T cells mitigate CNS autoimmunity[J].Glia,2004,47(2):168-179.
  • 9Roncarolo MG,Bacchetta R,Bordignon C,et al.Type 1 T regulatory cells[J].Imm Rev,2001,182:68-79.
  • 10Dieckmann D,Plottner H,Berchtold S,et al.Ex vivo isolation and characterization of CD4+CD25+T cells with regulatory properties from human blood[J].J Exp Med,2001,193(11):1303-1310.

同被引文献66

  • 1唐贤勇.急性期多发性硬化症采用大剂量甲基强的松龙治疗的疗效分析[J].现代养生,2014,0(10):154-155. 被引量:3
  • 2张骏.世界药物新闻(八十二)[J].天津药学,2006,18(5):75-76. 被引量:1
  • 3吕传真,李振新,张华,戚晓昆,臧敬五.中国多发性硬化及相关中枢神经系统脱髓鞘疾病的诊断和治疗专家共识(草案)[J].中华神经科杂志,2006,39(12):862-864. 被引量:55
  • 4贾建平.神经病学[M]6版北京:人民卫生出版社,2008:176.
  • 5王爱平.β-1a干扰素治疗多发性硬化症的临床观察[J].中国实用神经疾病杂志,2007,10(9):119-120. 被引量:3
  • 6Brajkovi6 L, Bras M, Milunovi5 V, et al. The connection be- tween coping mechanisms, depression, anxiety and fatigue in multiple sclerosis[J]. Coil Antropul, 2009,33 suppl 2:135 - 140.
  • 7Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Thera- peutics and Technology Assessment Subcommittee of the A- merican Academy of Neurology and the MS Council for Clinical Practice Guide[inesI-J]. Neurology, 2002,58(2) :169- 178.
  • 8Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induc- tion treatment in aggressive relapsing remitting multiple scle- rosis: treatment response factors in a 5 year follow-up obser- vational study of 100 consecutive patients[J]. J Neurol Neuro- surg Psychiatry,2008,79(1) :52-56.
  • 9Berger T, Deisenhammer F. Progressive multifocal leukoen- cephalopathy, natalizumab, and multiple sclerosis[J]. N Engl J Med,2005,353(16):1 744-1 746.
  • 10Baiter LJ, Galetta SL, Calabresi PA, et al. Natalizumab re- duces visual loss in patients with relapsing multiple sclerosis [J]. Neurology, 2007,68(16) : 1 299 - 1 304.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部